Wall Street Zen Downgrades Anixa Biosciences (NASDAQ:ANIX) to Sell

Anixa Biosciences (NASDAQ:ANIX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research firms have also recently issued reports on ANIX. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Thursday, September 11th. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Friday, December 12th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Anixa Biosciences presently has an average rating of “Hold” and a consensus target price of $9.00.

Anixa Biosciences Stock Performance

NASDAQ ANIX opened at $3.20 on Friday. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $5.46. The stock has a market cap of $105.34 million, a PE ratio of -9.14 and a beta of 0.49. The firm has a 50-day simple moving average of $4.15 and a 200 day simple moving average of $3.62.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIX. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences in the 2nd quarter valued at $33,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in Anixa Biosciences in the second quarter valued at about $37,000. Marshall Wace LLP acquired a new position in Anixa Biosciences in the second quarter valued at about $39,000. Finally, World Investment Advisors bought a new stake in Anixa Biosciences during the third quarter worth about $48,000. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.